- Potential benefitRequires in-person physician examination and follow-up for medication abortions, which supporters say improves medical…
- Potential benefitCurtails telehealth and mail-order distribution of abortion drugs, aligning practice with supporters' safety priorities.
- Potential benefitRestricts non-physician clinicians and remote pharmacies from furnishing medication abortions, reinforcing physician-ce…
Women’s Protection in Telehealth Act
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for c…
This bill amends Section 1128 of the Social Security Act to create a new Medicare exclusion for any individual or entity that prescribes, administers, dispenses, or furnishes an "abortion-inducing drug" after enactment unless the provider is a physician who performs a physical exam, is physically present in the same room when the drug is taken or administered, and schedules an in-person follow-up within 14 days. The measure defines "abortion-inducing drug" to include any drug intended to terminate a clinically diagnosable pregnancy (including off-label uses) and adopts the statutory definition of "unborn child." It makes exclusions under this new paragraph permanent and removes certain reinstatement or other subsection protections for such exclusions.
Progressives emphasize reduced access and harm to telehealth care.
Relatively narrow statutory change that appeals to constituents favoring abortion restrictions; House historically more likely to pass divisive, ideologically driven measures.
This bill amends Section 1128 of the Social Security Act to create a new Medicare exclusion for any individual or entity that prescribes, administers, dispenses, or furnishes an "abortion-inducing drug" after enactment unless the provider is a physician who performs a physical exam, is physically present in the same room when the drug is taken or administered, and schedules an in-person follow-up within 14 days.
The measure defines "abortion-inducing drug" to include any drug intended to terminate a clinically diagnosable pregnancy (including off-label uses) and adopts the statutory definition of "unborn child." It makes exclusions under this new paragraph permanent and removes certain reinstatement or other subsection protections for such exclusions.
The exclusion applies to participation in the Medicare program under Title XVIII and can affect individuals and entities providing the covered services.
Substantive, ideologically charged restriction with limited compromise features; plausible in lower chamber but faces significant obstacles in the Senate and legal scrutiny.
How solid the drafting looks.
Progressives emphasize reduced access and harm to telehealth care.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenReduces access to medication abortion in rural and underserved areas by eliminating telehealth and mail-order options.
- Potential burdenMay remove providers from Medicare participation, decreasing available clinicians for other Medicare-covered services.
- StatesPermanent exclusion without normal reinstatement or appeals increases regulatory severity and chilling effects on provi…
Why the argument around this bill splits.
Progressives emphasize reduced access and harm to telehealth care.
Likely to oppose the bill as an unnecessary restriction on access to medication abortion and telehealth care.
Would view the in-person and physician-only requirements as burdensome, likely to reduce access especially for rural and low-income patients.
Concerned that permanent Medicare exclusion is punitive and could chill providers from offering evidence-based telehealth services.
Mixed view: recognizes patient safety and physician oversight arguments but worries about access, workforce effects, and harsh permanent exclusions.
Would want narrower, evidence-based limits or built-in exceptions, and retention of due-process and reinstatement rights.
Sees tradeoffs between in-person care and telehealth efficiencies.
Likely to support the bill as protecting women by ensuring in-person physician oversight for abortion-inducing drugs and restricting remote provision.
Views the physician-only and in-room requirements as reasonable safety safeguards and the permanent exclusion as a strong enforcement mechanism.
Sees the measure as consistent with efforts to limit medication abortions via telehealth.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantive, ideologically charged restriction with limited compromise features; plausible in lower chamber but faces significant obstacles in the Senate and legal scrutiny.
- No CBO score or estimated administrative costs provided
- Unclear practical scope given Medicare patient population
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives emphasize reduced access and harm to telehealth care.
Substantive, ideologically charged restriction with limited compromise features; plausible in lower chamber but faces significant obstacles…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Women’s Protection in Telehealth Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.